
Nuvalent Inc
NUVLHealthcare|Biotechnology|USA
$123.90
+0.06 (+0.05%)
Tangible Book
$14.89
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
11.64,
181.96,
512.91,
921.43,
1257.67
],
"ebit_estimate": [
-486.98,
-394.64,
-134.8,
214.61,
523.47
],
"ebitda_estimate": [
-481.29,
-392.16,
-41.28,
2.13,
572.23
],
"net_income_estimate": [
-449.26,
-371.62,
-154.3,
233.27,
520.66
],
"per_share_eps_estimate": [
-5.73,
-4.44,
-1.11,
2.84,
5.34
],
"eps_nri_estimate": [
-5.68,
-4.55,
-1.6,
2.97,
5.06
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
14.96,
15.76,
35.85,
null,
null
],
"pretax_income_estimate": [
-454.06,
-370.86,
-125.3,
258.85,
571.86
],
"operating_cash_flow_per_share_estimate": [
-3.38,
-1.86,
6.19,
null,
null
],
"roa_estimate": [
-35.8,
-33.3,
null,
null,
null
],
"roe_estimate": [
-36.02,
-27.06,
20.86,
null,
null
],
"gross_margin_estimate": [
70.5,
74.83,
73.2,
65.33,
65.33
],
"operating_cash_flow_estimate": [
-265.91,
-146.33,
486.97,
null,
null
],
"pettm_estimate": [
0,
0,
0,
43.58,
23.19
],
"long_term_growth_rate_mean": 33.77,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 40.82,
"future_eps_nri_estimate_growth": 33.77,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 30.08,
"future_ebitda_estimate_growth": 50.95,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 27.62,
"future_pretax_income_estimate_growth": 32.06,
"future_book_value_per_share_estimate_growth": 28.16,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
null,
1.91,
9.65,
56.27,
34.05,
48.14,
62.5
],
"ebit_estimate": [
-120.35,
-122.25,
-118.79,
-53.69,
-106.03,
-98.33,
-94.02
],
"ebitda_estimate": [
-119.17,
-123.25,
-121.83,
-99.65,
-105.91,
-93.71,
-90.54
],
"net_income_estimate": [
-112.5,
-114.91,
-110.95,
-34.13,
-96.54,
-89.17,
-85.18
],
"per_share_eps_estimate": [
-1.42,
-1.45,
-1.41,
-0.94,
-1.2,
-1.04,
-0.77
],
"eps_nri_estimate": [
-1.41,
-1.44,
-1.4,
-0.97,
-1.21,
-1.05,
-0.79
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-113.8,
-116.7,
-113.63,
-34.13,
-96.54,
-89.17,
-85.18
],
"operating_cash_flow_per_share_estimate": [
-1.19,
-1.22,
-1.2,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
-34.97,
-36.68,
-28.43,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
46.5,
51,
95,
95,
95,
95
],
"operating_cash_flow_estimate": [
-93.62,
-95.98,
-94.4,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 33.77,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 40.82,
"future_eps_nri_estimate_growth": 33.77,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 30.08,
"future_ebitda_estimate_growth": 50.95,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 27.62,
"future_pretax_income_estimate_growth": 32.06,
"future_book_value_per_share_estimate_growth": 28.16,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}